Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Arctic Bioscience Investor Presentation 2021

Dec 16, 2021

3536_rns_2021-12-16_c2eda217-af6a-4a19-aca9-665c13d97381.html

Investor Presentation

Open in viewer

Opens in your device viewer

Arctic Bioscience - Presentation at DNB Healthcare Conference 2021

Arctic Bioscience - Presentation at DNB Healthcare Conference 2021

Arctic Bioscience, a biotech company developing and commercializing

nutraceutical and developing pharmaceutical products based on the unique

properties of bioactive marine compounds, will today participate at the DNB

Nordic Healthcare Conference 2021, presenting the company's goals, strategy and

priorities. The live session can be viewed at 11.10am on Stream 1 at DNB Nordic

Healthcare Conference 2021 Markets Session Stream

1 (https://scene.dnb.no/brandcenter/no/scene/component/default/64501).

In conjunction with this, the company has released a new company

presentation (https://arctic-bioscience.com/investors/reports-presentations/) on

its website.

A live recording of the presentation at the DNB conference will also be made

available on the company's website (https://arctic

-bioscience.com/investors/reports-presentations/).

For further information, please contact:

Danielle Glenn

CFO of Arctic Bioscience AS

Mobile: +47 909 98 201

Email: [email protected]

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

nutraceutical products based on herring roe oil. Herring roe oil contains lipids

that are essential to maintain cell membranes, contributing to normal

functioning of brain, heart, and vision. Nutraceuticals from Arctic Bioscience

are sold globally as bulk ingredients to other companies making dietary

supplements, and as finished goods under the Romega brand. The strategy is to

switch sales from bulk to finished goods and focus markets are USA and China.

The company is developing HRO350 - a novel investigational drug candidate with

herring roe as raw material. HRO350 is being developed for treatment of mild-to

-moderate psoriasis. This is a large patient group in need of new effective

medicines with beneficial safety profile. Arctic Bioscience is led by a team of

highly competent people with experience in developing marine oils and experience

from global pharmaceutical companies.